Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO
· Real-Time Price · USD
0.27
-0.03 (-10.00%)
At close: May 23, 2025, 3:59 PM
0.27
0.11%
After-hours: May 23, 2025, 05:55 PM EDT
Aptevo Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|
| Product Revenue | 32.4M | 23.07M |
| Product Revenue Growth | +40.46% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 2.85M | 2.5M | 2.11M | 2.38M | 3.23M | 2.79M | 2.67M | 2.72M | 3.59M | 3.01M | 3.31M | 3.7M | 3.86M | 3.16M | 3.48M | 4.11M | 3.95M | 4.28M | 3.21M | 2.84M | 3.62M | 4.99M | 6.48M | 6.54M | 7.33M | 6.58M | 6.94M | 7.02M | 7.59M | 8.56M | 7.47M | 8.76M | 10.55M | 8.71M | 11.68M | 8.86M | 9.42M | 14.14M | 8.51M | 10.46M | 9.93M |
| Selling, General, and Administrative Revenue Growth | +13.79% | +18.58% | -11.38% | -26.31% | +15.68% | +4.45% | -1.55% | -24.30% | +19.20% | -8.98% | -10.55% | -4.20% | +22.04% | -9.11% | -15.35% | +4.13% | -7.78% | +33.13% | +13.20% | -21.46% | -27.56% | -22.92% | -0.95% | -10.80% | +11.45% | -5.23% | -1.18% | -7.49% | -11.28% | +14.51% | -14.64% | -16.99% | +21.12% | -25.45% | +31.86% | -5.97% | -33.39% | +66.12% | -18.57% | +5.27% | n/a |
| Research and Development Revenue | 3.63M | 3.88M | 3.1M | 3.64M | 3.65M | 3.48M | 3.89M | 5.46M | 4.17M | 4.67M | 4.48M | 3.87M | 4.87M | 4.54M | 4.37M | 4.72M | 5.36M | 4.91M | 4.49M | 4.44M | 4.01M | 5.61M | 9.13M | 7.73M | 7.29M | 8.9M | 8.57M | 9.71M | 8.2M | 9.19M | 7.17M | 6.79M | 5.91M | 6.67M | 7.11M | 7.64M | 8.1M | 7.41M | 7.71M | 10.51M | 9.1M |
| Research and Development Revenue Growth | -6.37% | +25.04% | -14.82% | -0.08% | +4.92% | -10.60% | -28.84% | +31.05% | -10.83% | +4.40% | +15.83% | -20.57% | +7.11% | +4.03% | -7.52% | -11.94% | +9.16% | +9.30% | +1.22% | +10.83% | -28.64% | -38.48% | +18.00% | +6.15% | -18.14% | +3.79% | -11.73% | +18.47% | -10.74% | +28.03% | +5.70% | +14.80% | -11.31% | -6.28% | -6.84% | -5.74% | +9.37% | -3.95% | -26.59% | +15.44% | n/a |